Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Abbisko Completes Enrollment in Global Phase III Trial for Tenosynovial Giant Cell Tumor

publication date: Apr 11, 2024

Shanghai Abbisko Therapeutics has completed patient enrollment for a pivotal global Phase III trial of pimicotinib in patients with tenosynovial giant cell tumor (TGCT). Pimicotinib is a novel, orally available small molecule inhibitor of CSF-1R. TGCT is a benign tumor that can cause painful joint swelling and stiffness. In late 2023, Abbisko sold greater China commercial rights to the drug for TGCT to Germany’s Merck in a $605 million agreement, including $70 million upfront. Merck has an option to add global rights to the candidate. The trial enrolled 94 patients at sites in China, the US and EU. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital